Antiviral combinations
https://themeditary.com/dosage-information/vosevi-dosage-1161.html

Vosevi Dosage

Drug Detail:Vosevi (Sofosbuvir, velpatasvir, and voxilaprevir [ soe-fos-bue-vir, vel-pat-as-vir, and-vox-i-la-pre-vir ])

Generic Name: SOFOSBUVIR 400mg, VELPATASVIR 100mg, VOXILAPREVIR 100mg

Dosage Form: tablet, film coated

Drug Class: Antiviral combinations

Contents
Uses Warnings Before Taking Dosage Side effects Interactions FAQ

Testing Prior to the Initiation of Therapy

Test all patients for evidence of current or prior HBV infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before initiating HCV treatment with VOSEVI [see Warnings and Precautions (5.1)].

Recommended Dosage

The recommended dosage of VOSEVI is one tablet, taken orally, once daily with food [see Clinical Pharmacology (12.3)]. One tablet of VOSEVI contains 400 mg of sofosbuvir, 100 mg of velpatasvir, and 100 mg of voxilaprevir. Table 1 shows the recommended treatment regimen and duration based on patient population.

Table 1 Recommended Treatment Regimen and Duration in Adults Without Cirrhosis or With Compensated Cirrhosis (Child-Pugh A)
Genotype Patients Previously Treated with an HCV Regimen Containing: VOSEVI
Duration
*
In clinical trials, prior NS5A inhibitor experience included daclatasvir, elbasvir, ledipasvir, ombitasvir, or velpatasvir.
†
In clinical trials, prior treatment experience included sofosbuvir with or without any of the following: peginterferon alfa/ribavirin, ribavirin, HCV NS3/4A protease inhibitor (boceprevir, simeprevir, or telaprevir).
1, 2, 3, 4, 5, or 6 An NS5A inhibitor* 12 weeks
1a or 3 Sofosbuvir without an NS5A inhibitor† 12 weeks

Renal Impairment

​No dosage adjustment of VOSEVI is recommended in patients with any degree of renal impairment including patients on dialysis [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

Moderate or Severe Hepatic Impairment

VOSEVI is not recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) due to higher exposures of voxilaprevir in these patients [see Warnings and Precautions (5.2), Use in Specific Populations (8.7), and Clinical Pharmacology (12.3)].

Share this Article
Latest News
Related Drugs